Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 1/20 | 1.00 |
| ▸ | ASIC3 | Q9UHC3 | 2/20 | 0.59 |
| ▸ | KMO | O15229 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL284286 | 0.84 | ASIC3 (0.71) | MIFASIC3KMORAB9ANPC1 | |
| SCHEMBL27904874 | 0.81 | ASIC3 (0.68) | MIFASIC3KMORAB9ANPC1 | |
| SCHEMBL29406194 | 0.81 | ASIC3 (0.68) | MIFASIC3KMORAB9ANPC1 | |
| SCHEMBL28218682 | 0.81 | ASIC3 (0.68) | MIFASIC3KMORAB9ANPC1 | |
| SCHEMBL20813389 | 0.81 | MIF (0.68) | MIFASIC3KMORAB9ANPC1 | |
| SCHEMBL18731738 | 0.79 | ASIC3 (0.65) | MIFASIC3KMORAB9ANPC1 | |
| SCHEMBL29730373 | 0.79 | ASIC3 (0.65) | MIFASIC3KMORAB9ANPC1 | |
| SCHEMBL17697185 | 0.79 | ASIC3 (0.65) | MIFASIC3KMORAB9ANPC1 | |
| SCHEMBL1445248 | 0.79 | MIF (0.66) | MIFASIC3KMORAB9ANPC1 | |
| SCHEMBL1445134 | 0.79 | MIF (0.65) | MIFKMOKMT2AMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250135196-A1 | COMPOSITIONS, SYSTEMS, AND METHODS FOR TREATING CANCER USING TUMOR TREATING FIELDS WITH INHIBITORS OF MIF, MICA, AND/OR MICB | UNIV BROWN (US) | 2025-05-01 | — | — | US | claimed |
| CN-114028399-A | Application of MIF inhibitor 4-IPP in preparation of medicine for treating brain glioma | 郑琳 | 2022-02-11 | — | — | CN | claimed |
| US-9155790-B2 | Methods and compositions for modulating ocular damage | University of Lousiville Research Foundation, Inc. (US) | 2015-10-13 | — | — | US | claimed |
| US-8999984-B2 | Macrophage migration inhibitory factor antagonists and methods of using same | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2015-04-07 | — | — | US | claimed |
| US-20130177552-A1 | METHODS AND COMPOSITIONS FOR MODULATING OCULAR DAMAGE | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2013-07-11 | — | — | US | claimed |
| WO-2011146824-A1 | METHODS AND COMPOSITIONS FOR MODULATING OCULAR DAMAGE | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2011-11-24 | — | — | WO | claimed |
| US-20110009412-A1 | MACROPHAGE MIGRATION INHIBITORY FACTOR ANTAGONISTS AND METHODS OF USING SAME | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2011-01-13 | — | — | US | claimed |
| CN-101528039-A | Macrophage migration inhibitory factor antagonists and methods of using same | UNIV LOUISVILLE RES FOUND (US) | 2009-09-09 | — | — | CN | claimed |
| EP-2026654-A2 | MACROPHAGE MIGRATION INHIBITORY FACTOR ANTAGONISTS AND METHODS OF USING SAME | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2009-02-25 | — | — | EP | claimed |
| WO-2007140263-A9 | MACROPHAGE MIGRATION INHIBITORY FACTOR ANTAGONISTS AND METHODS OF USING SAME | UNIV LOUISVILLE RES FOUND (US) | 2008-04-03 | — | — | WO | claimed |
| WO-2007140263-A2 | MACROPHAGE MIGRATION INHIBITORY FACTOR ANTAGONISTS AND METHODS OF USING SAME | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2007-12-06 | — | — | WO | claimed |
| US-20260085468-A1 | METHODS AND SYSTEMS FOR DYE REMOVAL FROM POLYMER TEXTILES | ALLIANCE SUSTAINABLE ENERGY (US) | 2026-03-26 | — | — | US | disclosed |
| US-12428417-B2 | Inhibitors of macrophage migration inhibitory factor | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| EP-4615582-A1 | MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) TARGETING FOR THE TREATMENT OF NON-SMALL CELL LUNG CANCER | Board of Regents, The University of Texas System (US) | 2025-09-17 | — | — | EP | disclosed |
| WO-2025097084-A1 | BIOMARKER FOR FAMILIAL PLATELET DISORDER AND USES THEREOF | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2025-05-08 | — | — | WO | disclosed |
| CN-101528039-A | Macrophage migration inhibitory factor antagonists and methods of using same | UNIV LOUISVILLE RES FOUND (US) | 2009-09-09 | — | — | CN | disclosed |
| EP-2026654-A2 | MACROPHAGE MIGRATION INHIBITORY FACTOR ANTAGONISTS AND METHODS OF USING SAME | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2009-02-25 | — | — | EP | disclosed |
| WO-2007140263-A9 | MACROPHAGE MIGRATION INHIBITORY FACTOR ANTAGONISTS AND METHODS OF USING SAME | UNIV LOUISVILLE RES FOUND (US) | 2008-04-03 | — | — | WO | disclosed |
| WO-2007140263-A9 | MACROPHAGE MIGRATION INHIBITORY FACTOR ANTAGONISTS AND METHODS OF USING SAME | UNIV LOUISVILLE RES FOUND (US) | 2008-04-03 | — | — | WO | disclosed |
| WO-2007140263-A2 | MACROPHAGE MIGRATION INHIBITORY FACTOR ANTAGONISTS AND METHODS OF USING SAME | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250135196-A1 | COMPOSITIONS, SYSTEMS, AND METHODS FOR TREATING CANCER USING TUMOR TREATING FIELDS WITH INHIBITORS OF MIF, MICA, AND/OR MICB | MIF, MICA, CD74 | MIF 1/4885ASIC3 4275/4885KMO 4035/4885 |
| US-20260085468-A1 | METHODS AND SYSTEMS FOR DYE REMOVAL FROM POLYMER TEXTILES | MPO, CES2, AOC3 | MIF 4204/4885ASIC3 1070/4885KMO 771/4885 |
| US-20110009412-A1 | MACROPHAGE MIGRATION INHIBITORY FACTOR ANTAGONISTS AND METHODS OF USING SAME | MIF, MMP12, CCL2 | MIF 1/4885ASIC3 4508/4885KMO 3717/4885 |
| US-20130177552-A1 | METHODS AND COMPOSITIONS FOR MODULATING OCULAR DAMAGE | MIF, MMP1, CXCL12 | MIF 1/4885ASIC3 4353/4885KMO 2308/4885 |
| US-12428417-B2 | Inhibitors of macrophage migration inhibitory factor | MIF, CD209, F3 | MIF 1/4885ASIC3 1951/4885KMO 4063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.